Isquemia digital secundaria al empleo de terlipresina en un enfermo con síndrome hepatorrenal

2011, Number 3

Med Crit 2011; 25 (3)

Carrillo ER, Ramírez RFJ, Carrillo CJR, Carrillo CLD

Language: Spanish
References: 13
Page: 169-171
PDF size: 270.20 Kb.

Text Extraction

No abstract

REFERENCES

Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008;28:81-95.
Fabrizi F, Martin P, Messa P. Recent advances in the management of hepato-renal syndrome (HRS). Acta Clin Bel 2007;2:393-396.
Carl DE, Sanyal A. The management of hepatorenal syndrome. Minerva Gastroenterol Dietol 2009;55:207-226.
Testro AG, Angus PW. Targeting circulatory dysfunction in cirrhosis: terlipressin and the hepatorenal syndrome. J Gastroenterol Hepatol 2009;24:1707-1709.
Martín-Llahi M, Pepin MN, Guevara M, Díaz F, Torre A, Monescillo A. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008;134:1352-1359.
Fabrizi F, Dixit V, Messa P, Martin P. Terlipressin for hepatorenal syndrome. A meta-analysis of randomized trials. Int J Artif Organs 2009;32:133-140.
Gludd LL, Christensen K, Christensen E, Krag A. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010;51:576-584.
Saner FH, Canbay A, Gerken G, Broelsch CE. Pharmacology, clinical efficacy and safety of terlipressin in esophageal varices bleeding, septic shock and hepatorenal syndrome. Expert Rev Gastroenterol Hepatol 2007;1:207-217.